ciprofloxacin has been researched along with Cirrhosis, Liver in 36 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "For the treatment of spontaneous bacterial peritonitis (SBP), cefotaxime, ceftriaxone, and ciprofloxacin were used as first-line agents." | 9.69 | Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP. ( Baik, SK; Han, KH; Heo, J; Heo, NY; Jung, YK; Kang, SH; Kim, BI; Kim, HS; Kim, MY; Kim, TH; Kim, YS; Park, JY; Park, SY; Seo, YS; Sohn, JH; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2023) |
| "Once weekly ciprofloxacin was as effective as daily norfloxacin for the prevention of SBP in cirrhotic patients with ascites." | 9.27 | Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. ( Jang, JY; Jung, YK; Kim, BI; Kim, HS; Kim, YS; Lee, YR; Park, SY; Seo, YS; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2018) |
| "A total of 116 cirrhotic patients with spontaneous bacterial peritonitis, were randomly given switch therapy with ciprofloxacin (61 patients) or intravenous ceftazidime (55 patients)." | 9.12 | Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. ( Angeli, P; Antona, C; Brollo, L; Cillo, U; Craighero, R; Fasolato, S; Franchin, M; Gatta, A; Guarda, S; Merkel, C; Miola, E; Piccolo, F, 2006) |
| "The aim of this prospective double-blind study was to evaluate the value of long-term antibiotic prophylaxis using ciprofloxacin for the prevention of spontaneous bacterial peritonitis (SBP) in 60 cirrhotic patients with low ascitic fluid protein levels (< 15 g/L)." | 9.08 | Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. ( Bacq, Y; Bohn, B; Cordier, L; Franza, A; Fratte, S; Kitmacher, P; Nousbaum, JB; Paris, JC; Rolachon, A; Stahl, JP, 1995) |
| "The pharmacokinetics of ciprofloxacin were evaluated in 11 patients (3 patients with impaired renal function) with advanced liver cirrhosis after a single oral dose of 500 mg." | 7.68 | Pharmacokinetics of ciprofloxacin in liver cirrhosis. ( Borner, K; Hopfenmüller, W; Ruhnke, M; Trautmann, M, 1990) |
| "For the treatment of spontaneous bacterial peritonitis (SBP), cefotaxime, ceftriaxone, and ciprofloxacin were used as first-line agents." | 5.69 | Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP. ( Baik, SK; Han, KH; Heo, J; Heo, NY; Jung, YK; Kang, SH; Kim, BI; Kim, HS; Kim, MY; Kim, TH; Kim, YS; Park, JY; Park, SY; Seo, YS; Sohn, JH; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2023) |
| "Careful dosing and a high index of suspicion of the neurological adverse effects of ciprofloxacin including movement disorders are warranted especially in cirrhotic patients." | 5.35 | A case of hemiballism as a rare side effect of ciprofloxacin in a patient with liver cirrhosis. ( Jeong, SH; Kim, JM; Kim, JW; Kim, SH; Lee, SH, 2009) |
| " In all critically ill patients ciprofloxacin elimination was significantly slowed; the mean half-life was similarly prolonged to about 14 h in patients on haemofiltration and those with approximately normal renal function." | 5.31 | Pharmacokinetics of ciprofloxacin in patients with acute renal failure undergoing continuous venovenous haemofiltration: influence of concomitant liver cirrhosis. ( Bellmann, R; Bellmann-Weiler, R; Dunzendorfer, S; Egger, P; Gritsch, W; Joannidis, M; Wiedermann, ChJ, 2002) |
| "Once weekly ciprofloxacin was as effective as daily norfloxacin for the prevention of SBP in cirrhotic patients with ascites." | 5.27 | Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. ( Jang, JY; Jung, YK; Kim, BI; Kim, HS; Kim, YS; Lee, YR; Park, SY; Seo, YS; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2018) |
| "A total of 116 cirrhotic patients with spontaneous bacterial peritonitis, were randomly given switch therapy with ciprofloxacin (61 patients) or intravenous ceftazidime (55 patients)." | 5.12 | Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. ( Angeli, P; Antona, C; Brollo, L; Cillo, U; Craighero, R; Fasolato, S; Franchin, M; Gatta, A; Guarda, S; Merkel, C; Miola, E; Piccolo, F, 2006) |
| "In cirrhotic patients with variceal bleeding and with Child-Pugh class B or C, the use of intravenous ciprofloxacin for 3 days after EVL was not only effective in the prevention of bacterial infections but also cost-effective." | 5.10 | [Prospective randomized trial of intravenous ciprofloxacin for prevention of bacterial infection in cirrhotic patients with esophageal variceal bleeding]. ( Choi, KW; Choi, MS; Hong, SN; Kim, BJ; Kim, JJ; Koh, KC; Lee, CY; Lee, JH; Lee, SY; Paik, SW; Rhee, JC; Rhee, PL; Ryu, MK, 2002) |
| "The aim of this prospective double-blind study was to evaluate the value of long-term antibiotic prophylaxis using ciprofloxacin for the prevention of spontaneous bacterial peritonitis (SBP) in 60 cirrhotic patients with low ascitic fluid protein levels (< 15 g/L)." | 5.08 | Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. ( Bacq, Y; Bohn, B; Cordier, L; Franza, A; Fratte, S; Kitmacher, P; Nousbaum, JB; Paris, JC; Rolachon, A; Stahl, JP, 1995) |
| " The aim of this study was to investigate the efficacy of prophylactic intestinal decontamination with oral ciprofloxacin for the prevention of bacterial infections in cirrhotic patients with upper gastrointestinal bleeding." | 5.08 | The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding. ( Chang, FY; Hou, MC; Hsieh, WJ; Hwang, SJ; Lee, FY; Lee, SD; Lin, HC, 1998) |
| " For primary prophylaxis, short-term antibiotic treatment (oral norfloxacin or ciprofloxacin) is indicated in cirrhotic patients (with or without ascites) admitted with gastrointestinal haemorrhage (variceal or non-variceal)." | 4.84 | [Bacterial infections in liver cirrhosis]. ( Farkas, A; Papp, M; Tornai, I; Udvardy, M, 2007) |
| " Fluoroquinolones (norfloxacin and ciprofloxacin), third-generation cephalosporins (G3) (ceftriaxone and cefotaxime) and trimethoprim-sulfamethoxazole (SXT) are recommended for preventing infections in patients with cirrhosis or liver failure." | 4.12 | Evaluation of the current guidelines for antibacterial therapy strategies in patients with cirrhosis or liver failure. ( Dong, Y; Du, Q; Han, R; Shi, L; Sun, D; Teng, M; Wang, T; Wang, Y; Zhang, T; Zhang, Y; Zheng, G, 2022) |
| "In cirrhotic rats, ciprofloxacin suppressed endotoxemia and the hepatic endocannabinoid system thus ameliorating hyperdynamic circulation and decreased intrahepatic resistance by preventing hepatic fibrogenesis and endothelial dysfunction." | 3.77 | The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension. ( Huang, CM; Huang, YT; Lee, FY; Lee, SD; Lin, HC; Liu, TT; Tsai, TH; Yang, YY, 2011) |
| "The pharmacokinetics of ciprofloxacin were evaluated in 11 patients (3 patients with impaired renal function) with advanced liver cirrhosis after a single oral dose of 500 mg." | 3.68 | Pharmacokinetics of ciprofloxacin in liver cirrhosis. ( Borner, K; Hopfenmüller, W; Ruhnke, M; Trautmann, M, 1990) |
| "The pharmacokinetics of ciprofloxacin after a single 500 mg oral dose was studied in one group of healthy volunteers and in patients affected by liver cirrhosis and classified into three groups according to Child-Turcotte criteria." | 3.67 | Pharmacokinetics of ciprofloxacin in impaired liver function. ( Barba, D; Esposito, S; Miniero, M; Sagnelli, E, 1989) |
| "Ofloxacin kinetics were influenced by renal dysfunction encountered in patients with ascites." | 2.38 | Pharmacokinetics of fluoroquinolones in hepatic failure. ( Gaillot, J; Montay, G, 1990) |
| "Careful dosing and a high index of suspicion of the neurological adverse effects of ciprofloxacin including movement disorders are warranted especially in cirrhotic patients." | 1.35 | A case of hemiballism as a rare side effect of ciprofloxacin in a patient with liver cirrhosis. ( Jeong, SH; Kim, JM; Kim, JW; Kim, SH; Lee, SH, 2009) |
| " In all critically ill patients ciprofloxacin elimination was significantly slowed; the mean half-life was similarly prolonged to about 14 h in patients on haemofiltration and those with approximately normal renal function." | 1.31 | Pharmacokinetics of ciprofloxacin in patients with acute renal failure undergoing continuous venovenous haemofiltration: influence of concomitant liver cirrhosis. ( Bellmann, R; Bellmann-Weiler, R; Dunzendorfer, S; Egger, P; Gritsch, W; Joannidis, M; Wiedermann, ChJ, 2002) |
| "A 73-year-old woman with liver cirrhosis who developed H." | 1.30 | Haemophilus aphrophilus bacteraemia complicated with vertebral osteomyelitis and spinal epidural abscess in a patient with liver cirrhosis. ( Chang, SC; Chen, YC; Fang, CT; Hsieh, WC; Hsueh, PR; Hung, CC; Luh, KT, 1997) |
| "Ciprofloxacin was given orally at the starting dose of 250 mg every 12 hours for 7 days followed by a single dose of 250 mg/day from day 7 to day 14 and 125 mg/day for the next 3 weeks." | 1.30 | Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis. ( Borzio, M; Fragiacomo, L; Galvagno, D; Piantoni, L; Salerno, F; Saudelli, M, 1997) |
| "In order to develop a population pharmacokinetic model for ciprofloxacin after single oral dosing in patients with liver impairments, a retrospective population analysis of already published data was undertaken." | 1.30 | Population pharmacokinetics of ciprofloxacin in patients with liver impairments analyzed by NPEM2 algorithm--a retrospective study. ( Atanasova, I; Dimitrova, V; Terziivanov, D, 1998) |
| "Ciprofloxacin is an effective drug for initial treatment of SBP/CNNA." | 1.29 | Frequency, microbial spectrum and outcome of spontaneous bacterial peritonitis in north India. ( Ayyagari, A; Ghoshal, UC; Naik, SR; Puri, AS; Puri, J; Saraswat, VA; Sharma, BC, 1996) |
| " The pharmacokinetic parameters for ciprofloxacin were not significantly altered in cirrhotic patients." | 1.28 | The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. ( Frost, RW; Krol, G; Lasseter, KC; Lettieri, JT; Shamblen, EC, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.56) | 18.7374 |
| 1990's | 15 (41.67) | 18.2507 |
| 2000's | 6 (16.67) | 29.6817 |
| 2010's | 11 (30.56) | 24.3611 |
| 2020's | 2 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, Y | 2 |
| Sun, D | 1 |
| Wang, Y | 1 |
| Du, Q | 1 |
| Zhang, Y | 1 |
| Han, R | 1 |
| Teng, M | 1 |
| Zhang, T | 1 |
| Shi, L | 1 |
| Zheng, G | 1 |
| Wang, T | 1 |
| Yim, HJ | 2 |
| Kim, TH | 1 |
| Suh, SJ | 2 |
| Yim, SY | 2 |
| Jung, YK | 2 |
| Seo, YS | 2 |
| Kang, SH | 1 |
| Kim, MY | 1 |
| Baik, SK | 1 |
| Kim, HS | 3 |
| Kim, YS | 2 |
| Park, SY | 2 |
| Kim, BI | 3 |
| Park, JY | 1 |
| Heo, J | 1 |
| Sohn, JH | 1 |
| Heo, NY | 1 |
| Han, KH | 1 |
| Um, SH | 2 |
| Mo, S | 1 |
| Bendtsen, F | 1 |
| Wiese, SS | 1 |
| Kimer, N | 1 |
| Lee, YR | 1 |
| Jang, JY | 1 |
| Vinnitskaia, EV | 1 |
| Drozdov, VN | 1 |
| Petyrakov, AV | 1 |
| Sil'vestrova, SIu | 1 |
| Brezgin, AG | 1 |
| Nazir, S | 1 |
| Brown, K | 1 |
| Shin, AK | 1 |
| Donato, AA | 1 |
| Lutz, P | 1 |
| Nischalke, HD | 1 |
| Krämer, B | 1 |
| Goeser, F | 1 |
| Kaczmarek, DJ | 1 |
| Schlabe, S | 1 |
| Parcina, M | 1 |
| Nattermann, J | 1 |
| Hoerauf, A | 1 |
| Strassburg, CP | 1 |
| Spengler, U | 1 |
| Kim, SH | 1 |
| Jeong, SH | 1 |
| Kim, JW | 1 |
| Lee, SH | 1 |
| Kim, JM | 1 |
| Lin, HC | 2 |
| Yang, YY | 1 |
| Tsai, TH | 1 |
| Huang, CM | 1 |
| Huang, YT | 1 |
| Lee, FY | 2 |
| Liu, TT | 1 |
| Lee, SD | 2 |
| Fukui, H | 1 |
| Kim, HJ | 1 |
| Park, JH | 1 |
| Park, DI | 1 |
| Cho, YK | 1 |
| Sohn, CI | 1 |
| Jeon, WK | 1 |
| Kim, DJ | 1 |
| Senzolo, M | 1 |
| Nadal, E | 1 |
| Cholongitas, E | 1 |
| Burroughs, AK | 1 |
| Tsui, TL | 1 |
| Tsao, SM | 1 |
| Liu, KS | 1 |
| Chen, TY | 1 |
| Wang, YL | 1 |
| Teng, YH | 1 |
| Lee, YT | 1 |
| Reuken, PA | 1 |
| Pletz, MW | 1 |
| Baier, M | 1 |
| Pfister, W | 1 |
| Stallmach, A | 1 |
| Bruns, T | 1 |
| Bellmann, R | 1 |
| Egger, P | 1 |
| Gritsch, W | 1 |
| Bellmann-Weiler, R | 1 |
| Joannidis, M | 1 |
| Dunzendorfer, S | 1 |
| Wiedermann, ChJ | 1 |
| Hong, SN | 1 |
| Kim, BJ | 1 |
| Lee, SY | 1 |
| Lee, CY | 1 |
| Ryu, MK | 1 |
| Choi, MS | 1 |
| Lee, JH | 1 |
| Rhee, PL | 1 |
| Koh, KC | 1 |
| Kim, JJ | 1 |
| Paik, SW | 1 |
| Rhee, JC | 1 |
| Choi, KW | 1 |
| Angeli, P | 1 |
| Guarda, S | 1 |
| Fasolato, S | 1 |
| Miola, E | 1 |
| Craighero, R | 1 |
| Piccolo, F | 1 |
| Antona, C | 1 |
| Brollo, L | 1 |
| Franchin, M | 1 |
| Cillo, U | 1 |
| Merkel, C | 1 |
| Gatta, A | 1 |
| Wang, CY | 1 |
| Chuang, YM | 1 |
| Teng, LJ | 1 |
| Lee, LN | 1 |
| Yang, PC | 1 |
| Kuo, SH | 1 |
| Hsueh, PR | 3 |
| Papp, M | 1 |
| Farkas, A | 1 |
| Udvardy, M | 1 |
| Tornai, I | 1 |
| Rolachon, A | 1 |
| Cordier, L | 1 |
| Bacq, Y | 1 |
| Nousbaum, JB | 1 |
| Franza, A | 1 |
| Paris, JC | 1 |
| Fratte, S | 1 |
| Bohn, B | 1 |
| Kitmacher, P | 1 |
| Stahl, JP | 1 |
| Chan, TY | 1 |
| Chow, DP | 1 |
| Ng, KC | 1 |
| Pang, KW | 1 |
| McBride, GA | 1 |
| Castiella, A | 1 |
| Yuste, R | 1 |
| Gonzalez, F | 1 |
| Martinez, S | 1 |
| Alzate, L | 1 |
| Arriola, JA | 1 |
| Arenas, JI | 1 |
| Wu, JJ | 1 |
| Hsiue, TR | 1 |
| Hsieh, WC | 2 |
| Marmorale, A | 1 |
| Mainguene, C | 1 |
| Gavelli, A | 1 |
| Huguet, C | 1 |
| Puri, AS | 1 |
| Puri, J | 1 |
| Ghoshal, UC | 1 |
| Sharma, BC | 1 |
| Saraswat, VA | 1 |
| Ayyagari, A | 1 |
| Naik, SR | 1 |
| Gerbes, AL | 1 |
| Hung, CC | 1 |
| Chen, YC | 1 |
| Fang, CT | 1 |
| Chang, SC | 1 |
| Luh, KT | 1 |
| Borzio, M | 1 |
| Salerno, F | 1 |
| Saudelli, M | 1 |
| Galvagno, D | 1 |
| Piantoni, L | 1 |
| Fragiacomo, L | 1 |
| Hsieh, WJ | 1 |
| Hwang, SJ | 1 |
| Hou, MC | 1 |
| Chang, FY | 1 |
| Terziivanov, D | 1 |
| Atanasova, I | 1 |
| Dimitrova, V | 1 |
| Terg, R | 1 |
| Llano, K | 1 |
| Cobas, SM | 1 |
| Brotto, C | 1 |
| Barrios, A | 1 |
| Levi, D | 1 |
| Wasen, W | 1 |
| Bartellini, MA | 1 |
| Ortiz, J | 1 |
| Vila, MC | 1 |
| Soriano, G | 1 |
| Miñana, J | 1 |
| Gana, J | 1 |
| Mirelis, B | 1 |
| Novella, MT | 1 |
| Coll, S | 1 |
| Sábat, M | 1 |
| Andreu, M | 1 |
| Prats, G | 1 |
| Solá, R | 1 |
| Guarner, C | 1 |
| Montay, G | 1 |
| Gaillot, J | 1 |
| Ruhnke, M | 1 |
| Trautmann, M | 1 |
| Borner, K | 1 |
| Hopfenmüller, W | 1 |
| Esposito, S | 1 |
| Miniero, M | 1 |
| Barba, D | 1 |
| Sagnelli, E | 1 |
| Frost, RW | 1 |
| Lettieri, JT | 1 |
| Krol, G | 1 |
| Shamblen, EC | 1 |
| Lasseter, KC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Terlipressin Given As I.V. Boluses Vs Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome (Hrs): Preliminary Results Of A Randomized Controlled Clinical Study.[NCT00742690] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2005-05-31 | Recruiting | ||
| Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis: an Open, Randomized, Controlled Clinical Trial[NCT01455246] | Phase 2/Phase 3 | 32 participants (Actual) | Interventional | 2010-10-31 | Terminated (stopped due to Decision of independent monitoring committee after interim analysis: Risk of failure significantly higher in ceftazidime group.) | ||
| Comparison of Daily Norfloxacin Versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients[NCT01542801] | Phase 4 | 124 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for ciprofloxacin and Cirrhosis, Liver
| Article | Year |
|---|---|
[Spontaneous bacterial peritonitis in liver cirrhosis: optimization issues of prevention and treatment].
Topics: Anti-Infective Agents; Ascitic Fluid; Bacterial Infections; Ciprofloxacin; Female; Humans; Liver Cir | 2012 |
[Bacterial infections in liver cirrhosis].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ascites; | 2007 |
Pharmacokinetics of fluoroquinolones in hepatic failure.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Female; Ha | 1990 |
9 trials available for ciprofloxacin and Cirrhosis, Liver
| Article | Year |
|---|---|
Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Ascites; Bacterial Infections; Cefotaxime; Ceftriaxo | 2023 |
Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Ascites; Bacterial Infections; Ciprofloxacin; Disease-Free Survi | 2018 |
Increased intestinal permeability as a predictor of bacterial infections in patients with decompensated liver cirrhosis and hemorrhage.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Bacterial Infections; Bacterial Translocation; C | 2011 |
[Prospective randomized trial of intravenous ciprofloxacin for prevention of bacterial infection in cirrhotic patients with esophageal variceal bleeding].
Topics: Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; End | 2002 |
Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost.
Topics: Administration, Oral; Albumins; Anti-Bacterial Agents; Antihypertensive Agents; Ceftazidime; Ciprofl | 2006 |
Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost.
Topics: Administration, Oral; Albumins; Anti-Bacterial Agents; Antihypertensive Agents; Ceftazidime; Ciprofl | 2006 |
Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost.
Topics: Administration, Oral; Albumins; Anti-Bacterial Agents; Antihypertensive Agents; Ceftazidime; Ciprofl | 2006 |
Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost.
Topics: Administration, Oral; Albumins; Anti-Bacterial Agents; Antihypertensive Agents; Ceftazidime; Ciprofl | 2006 |
Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial.
Topics: Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Ascites; Bacterial Infections; Ciproflox | 1995 |
[Antibiotic prophylaxis after gastrointestinal hemorrhage in liver cirrhosis--for which patients, with what antibiotics?].
Topics: Amoxicillin-Potassium Clavulanate Combination; Antibiotic Prophylaxis; Bacterial Infections; Ciprofl | 1997 |
The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding.
Topics: Acute Disease; Administration, Oral; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fem | 1998 |
Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration, with daily and weekly dosages.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, | 1998 |
24 other studies available for ciprofloxacin and Cirrhosis, Liver
| Article | Year |
|---|---|
Evaluation of the current guidelines for antibacterial therapy strategies in patients with cirrhosis or liver failure.
Topics: Anti-Bacterial Agents; Cefotaxime; Ciprofloxacin; Humans; Liver Cirrhosis; Liver Failure | 2022 |
Low ascitic fluid total protein levels is not associated to the development of spontaneous bacterial peritonitis in a cohort of 274 patients with cirrhosis.
Topics: Anti-Bacterial Agents; Ascites; Ascitic Fluid; Bacterial Infections; Biomarkers; Ciprofloxacin; Denm | 2018 |
Vibrio vulnificus infection and liver cirrhosis: a potentially lethal combination.
Topics: Adult; Animals; Ciprofloxacin; Debridement; Doxycycline; Early Diagnosis; Humans; Liver Cirrhosis; M | 2016 |
Antibiotic resistance in healthcare-related and nosocomial spontaneous bacterial peritonitis.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Ceftriaxone; Ciprofloxacin; Cross Infection; Drug | 2017 |
A case of hemiballism as a rare side effect of ciprofloxacin in a patient with liver cirrhosis.
Topics: Ciprofloxacin; Dyskinesia, Drug-Induced; Female; Hepatitis B; Humans; Liver Cirrhosis; Magnetic Reso | 2009 |
The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension.
Topics: Animals; Anti-Bacterial Agents; Cannabinoid Receptor Modulators; Ciprofloxacin; Disease Models, Anim | 2011 |
How leaky gut and endotoxemia induce bacterial infection in cirrhosis and gastrointestinal hemorrhage?
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Bacterial Translocation; Cephalos | 2011 |
Is hydrophobia necessary for the hepatologist prescribing nonselective beta-blockers in cirrhosis?
Topics: Adrenergic beta-Antagonists; Aged; Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, | 2011 |
Comamonas testosteroni infection in Taiwan: Reported two cases and literature review.
Topics: Aged; Alcoholism; Anti-Bacterial Agents; Bacteremia; Carcinoma, Hepatocellular; Cellulitis; Cephalos | 2011 |
Emergence of spontaneous bacterial peritonitis due to enterococci - risk factors and outcome in a 12-year retrospective study.
Topics: Aged; Analysis of Variance; Anti-Infective Agents; Ascitic Fluid; Cephalosporins; Ciprofloxacin; Ent | 2012 |
Pharmacokinetics of ciprofloxacin in patients with acute renal failure undergoing continuous venovenous haemofiltration: influence of concomitant liver cirrhosis.
Topics: Acute Kidney Injury; Anti-Infective Agents; Area Under Curve; Chromatography, High Pressure Liquid; | 2002 |
Bacteraemic pneumonia caused by Neisseria lactamica with reduced susceptibility to penicillin and ciprofloxacin in an adult with liver cirrhosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Bacteremia; Base Sequence; Ceftriaxone; Ciprofl | 2006 |
Vibrio vulnificus septicemia in a patient with liver cirrhosis.
Topics: Animals; Bacteremia; Brachyura; Ceftazidime; Ciprofloxacin; Drug Therapy, Combination; Female; Hepat | 1994 |
[Infection of ascitic fluid caused by Campylobacter jejuni in a patient with liver cirrhosis. A new case with an atypical presentation].
Topics: Ascitic Fluid; Campylobacter Infections; Campylobacter jejuni; Ciprofloxacin; Humans; Liver Cirrhosi | 1994 |
Bacteremic necrotizing fasciitis due to Flavobacterium odoratum.
Topics: Aged; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Drug Resistance, Multiple; Fasciitis, Necrot | 1995 |
[Pure angiocholitic form of congenital hepatic fibrosis].
Topics: Anti-Infective Agents; Cholangitis; Ciprofloxacin; Combined Modality Therapy; Female; Humans; Liver | 1996 |
Frequency, microbial spectrum and outcome of spontaneous bacterial peritonitis in north India.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Cohort Stu | 1996 |
Haemophilus aphrophilus bacteraemia complicated with vertebral osteomyelitis and spinal epidural abscess in a patient with liver cirrhosis.
Topics: Abscess; Aged; Bacteremia; Cefotaxime; Ciprofloxacin; Epidural Space; Female; Haemophilus; Haemophil | 1997 |
Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis.
Topics: Administration, Oral; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciproflox | 1997 |
Population pharmacokinetics of ciprofloxacin in patients with liver impairments analyzed by NPEM2 algorithm--a retrospective study.
Topics: Administration, Oral; Algorithms; Anti-Infective Agents; Bayes Theorem; Bias; Ciprofloxacin; Female; | 1998 |
Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Ciprofloxacin; Drug Resi | 1999 |
Pharmacokinetics of ciprofloxacin in liver cirrhosis.
Topics: Administration, Oral; Adult; Ciprofloxacin; Female; Humans; Kidney Diseases; Liver Cirrhosis; Male; | 1990 |
Pharmacokinetics of ciprofloxacin in impaired liver function.
Topics: Adult; Ciprofloxacin; Female; Humans; Liver; Liver Cirrhosis; Male; Middle Aged | 1989 |
The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin.
Topics: Administration, Oral; Aged; Anti-Infective Agents; Biotransformation; Chromatography, High Pressure | 1989 |